Cite
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
MLA
Pratt, Edward, et al. “Orforglipron (LY3502970), a Novel, Oral Non‐peptide Glucagon‐like Peptide‐1 Receptor Agonist: A Phase 1b, Multicentre, Blinded, Placebo‐controlled, Randomized, Multiple‐ascending‐dose Study in People with Type 2 Diabetes.” Diabetes, Obesity & Metabolism, vol. 25, no. 9, Sept. 2023, pp. 2642–49. EBSCOhost, https://doi.org/10.1111/dom.15150.
APA
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023). Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes. Diabetes, Obesity & Metabolism, 25(9), 2642–2649. https://doi.org/10.1111/dom.15150
Chicago
Pratt, Edward, Xiaosu Ma, Rong Liu, Deborah Robins, Tamer Coskun, Kyle W. Sloop, Axel Haupt, and Charles Benson. 2023. “Orforglipron (LY3502970), a Novel, Oral Non‐peptide Glucagon‐like Peptide‐1 Receptor Agonist: A Phase 1b, Multicentre, Blinded, Placebo‐controlled, Randomized, Multiple‐ascending‐dose Study in People with Type 2 Diabetes.” Diabetes, Obesity & Metabolism 25 (9): 2642–49. doi:10.1111/dom.15150.